March 10, 2026 a 09:00 pm
BDX: Analysts Ratings - Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) continues to be a stable player in the medical supplies and devices industry. With strong demand across its various segments, the company has maintained a dominant position in healthcare. Current analyst ratings suggest a cautious optimism, with a noticeable trend towards a more conservative outlook in recent months.
Historical Stock Grades
The most recent analyst ratings for BDX indicate a balanced outlook with no strong sell or sell recommendations. The data as of March 2026 is as follows:
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 4 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around BDX has shown a shift over the past months. Notable observations are:
- There has been a consistent number of Hold ratings, indicating stability but also cautiousness in expectations.
- A slight decrease in Buy recommendations from 9 to 4 over the year, pointing towards a more neutral market sentiment.
- Strong Buy ratings remained constant but low, suggesting limited market aggression towards BDX stocks.
Percentage Trends
Analyzing the percentage distribution of ratings highlights some shifts:
- Strong Buy: Consistently remains low with a notable reduction from early 2025.
- Buy: A decline in percentage share, indicating cautious sentiment towards aggressive investments.
- Hold: A significant increase, suggesting a shift towards a wait-and-see approach among analysts.
- The overall sentiment has somewhat moderated with a marked shift from bullish to more cautious positions.
Latest Analyst Recommendations
Recent analyst recommendations suggest stability in opinion, with most ratings being maintained:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-11 | Buy | Buy | Citigroup |
| 2026-02-10 | Neutral | Neutral | Piper Sandler |
| 2026-02-10 | Buy | Buy | Jefferies |
| 2026-02-10 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-02-10 | Neutral | Neutral | JP Morgan |
Analyst Recommendations with Change of Opinion
A look into alterations in opinions reveals some pivotal shifts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-22 | Neutral | Buy | Citigroup |
| 2025-05-02 | Neutral | Overweight | Piper Sandler |
| 2025-05-01 | Market Perform | Outperform | William Blair |
| 2024-10-01 | Buy | Neutral | Citigroup |
| 2023-07-24 | Outperform | Market Perform | Raymond James |
Interpretation
The current market assessment for BDX reflects a cautious yet stable perspective. While the company remains a significant player in its field, the plateau in analyst ratings suggests a balanced view on its growth and risk profile. The trend towards more Hold ratings and fewer Buy recommendations indicates growing uncertainty or potential market risks. However, the lack of Sell or Strong Sell ratings illustrates continued confidence in BDX's long-term viability. Analyst opinion appears steady, but signs of caution are notable.
Conclusion
In conclusion, Becton, Dickinson and Company exhibits a blend of opportunity and risk. Analyst ratings have shifted towards a more cautious stance, with a rise in Hold recommendations suggesting a conservative outlook. While the company’s enduring market presence underpins analyst confidence, the decline in Buy ratings points to tempered growth expectations. Investors may view BDX as a stable yet currently undervalued long-term prospect, amid broader market hesitancy. Overall, understanding these dynamics is essential for assessing potential investment strategies around BDX.